Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-11-03Clinical Trial Update: Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies [Phase 2]
Phase 2 trial evaluating nivolumab in patients with hematologic malignancies after CAR-T therapy; results have been posted with the study cu…
-
CLINICAL_TRIALS trial_result · 2025-10-28Clinical Trial Update: Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) [Phase 2]
Phase 2 clinical trial update for epcoritamab in newly diagnosed marginal zone lymphoma, currently recruiting across MZL subtypes.
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) [Phase 1]
Phase I clinical trial update for BR101801 in adults with advanced hematologic malignancies; the study has completed.
-
CLINICAL_TRIALS trial_result · 2025-09-05Clinical Trial Update: [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma [Phase 3]
Phase 3 trial evaluating [68Ga]Ga-PentixaFor PET imaging for staging Marginal Zone Lymphoma has been terminated; sponsor Pentixapharm AG rep…
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers [Phase 1]
This is a Phase 1 clinical trial update for a CAR T cell therapy (19(T2)28z1xx) in various B-cell cancers. The study is sponsored by Memoria…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies [Phase 1]
Acepodia Biotech's Phase 1 trial of ACE1831 in adults with relapsed/refractory CD20-expressing B-cell malignancies is currently recruiting a…
-
CLINICAL_TRIALS trial_result · 2025-07-10Clinical Trial Update: Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. [Phase 3]
A phase 3 trial comparing lenalidomide plus rituximab followed by lenalidomide versus rituximab maintenance in relapsed/refractory follicula…
-
CLINICAL_TRIALS trial_result · 2025-07-08Clinical Trial Update: Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)
This clinical trial update summarizes completed results from a surveillance study of Revlimid (lenalidomide) in relapsed or refractory folli…
-
CLINICAL_TRIALS trial_result · 2025-07-02Clinical Trial Update: A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma [Phase 2]
This clinical trial update describes a Phase II study evaluating rituximab plus venetoclax as frontline therapy for marginal zone lymphoma, …
-
CLINICAL_TRIALS trial_result · 2025-06-24Clinical Trial Update: Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update on a Phase 1/2 study of lenalidomide in combination with obinutuzumab for relapsed indolent non-Hodgkin lymphoma, incl…
-
CLINICAL_TRIALS trial_result · 2025-06-18Clinical Trial Update: A Phase 1 Study of ADI-001 in B Cell Malignancies [Phase 1]
The Phase 1 study of ADI-001 in B cell malignancies has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-06-15Clinical Trial Update: Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating orelabrutinib in combination with rituximab as first-line systemic therapy for marginal zone lymphoma…
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating dendritic cell therapy with cryosurgery and pembrolizumab in various Non-Hodgkin lymphoma subtypes, w…
-
CLINICAL_TRIALS trial_result · 2025-05-14Clinical Trial Update: Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A phase 1/2 trial evaluated a conditioning regimen incorporating venetoclax, carmustine, etoposide, cytarabine, and melphalan before stem ce…
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]
Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory …
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
Clinical trial update on a Phase I/II study evaluating the safety of autologous CD20 CAR-T cells in relapsed or refractory B-cell non-Hodgki…
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating mosunetuzumab with or without polatuzumab vedotin and obinutuzumab for untreated indolent B-cell non-Hod…
-
CLINICAL_TRIALS trial_result · 2025-04-06Clinical Trial Update: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma [Phase 2]
Phase 2 trial of HMPL-689 for relapsed/refractory marginal zone lymphoma and follicular lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. [Phase 3]
Phase 3 trial evaluating tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in relapsed/refractory f…
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: Obinutuzumab in Marginal Zone Lymphoma [Phase 2]
This update reports an ongoing Phase 2 clinical trial of obinutuzumab for marginal zone lymphoma, currently active and not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-02-12Clinical Trial Update: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies [Phase 1, Phase 2]
This completed Phase 1/2 trial evaluates the combination of cirmtuzumab and ibrutinib in patients with B-cell lymphoid malignancies, includi…
-
CLINICAL_TRIALS trial_result · 2025-02-04Clinical Trial Update: Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies [Phase 1]
Phase 1 VENOM trial evaluating venetoclax with obinutuzumab and magrolimab in relapsed and refractory indolent B-cell malignancies has compl…
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
A completed clinical trial investigated the role of large extracellular vesicles as biomarkers in various lymphomas and lymphoproliferative …
-
CLINICAL_TRIALS trial_result · 2024-12-11Clinical Trial Update: TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 1]
Phase 1 trial evaluating SD-101 (TLR9 agonist) and BMS-986178 (anti-OX40 antibody) with radiation therapy for low-grade B-cell non-Hodgkin l…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating SD-101 (TLR9 agonist) combined with Ibrutinib and radiation therapy in relapsed or refractory follicular lympho…